PetMed Express Inc. (NASDAQ:PETS) CEO Menderes Akdag sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $20.75, for a total transaction of $207,500.00. Following the sale, the chief executive officer now owns 610,000 shares in the company, valued at approximately $12,657,500. The transaction was disclosed in a document filed with the SEC, which is available at this link.
PetMed Express Inc. (NASDAQ:PETS) opened at 20.23 on Friday. The company has a market cap of $408.24 million, a P/E ratio of 19.27 and a beta of 1.13. PetMed Express Inc. has a 52 week low of $15.61 and a 52 week high of $21.16. The company has a 50-day moving average of $20.34 and a 200 day moving average of $19.10.
PetMed Express (NASDAQ:PETS) last released its quarterly earnings results on Monday, July 25th. The company reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. PetMed Express had a net margin of 9.09% and a return on equity of 25.97%. The business earned $72.50 million during the quarter. During the same period in the prior year, the firm earned $0.29 EPS. PetMed Express’s quarterly revenue was up 1.3% on a year-over-year basis. On average, equities analysts forecast that PetMed Express Inc. will post $1.11 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in PETS. Societe Generale bought a new position in PetMed Express during the second quarter worth approximately $2,286,000. SG Americas Securities LLC bought a new position in PetMed Express during the second quarter worth approximately $2,286,000. WBI Investments Inc. bought a new position in PetMed Express during the second quarter worth approximately $1,906,000. Royce & Associates LP boosted its position in PetMed Express by 33.2% in the first quarter. Royce & Associates LP now owns 401,500 shares of the company’s stock worth $7,191,000 after buying an additional 100,000 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in PetMed Express during the second quarter worth approximately $1,483,000. 75.97% of the stock is owned by institutional investors and hedge funds.
Several analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of PetMed Express from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 27th. Credit Suisse Group AG reissued a “sell” rating and issued a $13.00 price objective on shares of PetMed Express in a research note on Tuesday, August 16th.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.